Pub. Date : 2019 Apr
PMID : 29166829
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | In patients with deleterious BRCA1/2 mutation, an overall response rate of 80% was achieved in the phase II trial Assessment of Rucaparib in Ovarian CancEr Trial 2 (ARIEL2). | rucaparib | BRCA1 DNA repair associated | Homo sapiens |
| 2 | CONCLUSION: Rucaparib appears to be a safe and effective new option in the treatment of relapsed, advanced BRCA1/2 mutant ovarian cancer. | rucaparib | BRCA1 DNA repair associated | Homo sapiens |